Table 1 The association between BRAF mutation status and clinicopathologic parameters
BRAF (+) | BRAF (−) | p valueb | |
|---|---|---|---|
Age, mean ± SDa | 56.25 ± 24.55 | 63.03 ± 12.03 | 0.926 |
Age category, n (%) | |||
< 65 years | 3 (7.5) | 23 (57.5) | 1.000 |
> 65 years | 1 (2.5) | 13 (32.5) | |
Sex, n (%) | |||
Male | 2 (5.0) | 14 (35.0) | 1.000 |
Female | 2 (5.0) | 22 (55.0) | |
Anatomic location, n (%) | |||
Extremity | 1 (2.5) | 32 (80.0) | 0.013 |
Central | 3 (7.5) | 4 (10.0) | |
Lymph node metastasis, n (%) | |||
Present | 2 (5.0) | 15 (37.5) | 1.000 |
Absent | 2 (5.0) | 21 (52.5) | |
Tumor thickness, n (%) | |||
≤ 4 mm | 1 (2.5) | 5 (12.5) | 0.493 |
> 4 mm | 3 (7.5) | 31 (77.5) | |
Ulceration, n (%) | |||
Present | 2 (5.0) | 21 (52.5) | 1.000 |
Absent | 2 (5.0) | 15 (37.5) | |
Mitotic index, mean ± SDa | 28.25 ± 17.60 | 22.11 ± 17.67 | 0.487 |
Mitotic index category, n (%) | |||
≥ 20% | 3 (7.5) | 16 (40.0) | 0.331 |
< 20% | 1 (2.5) | 20 (50.0) | |
Necrosis, n (%) | |||
Present | 2 (5.0) | 26 (65.0) | 0.570 |
Absent | 2 (5.0) | 10 (25.0) | |
Lymphovascular invasion, n (%) | |||
Present | 4 (10.0) | 8 (20.0) | 0.005 |
Absent | 0 (0.0) | 28 (70.0) | |
Tumor-infiltrating lymphocytes, n (%) | |||
Present | 4 (10.0) | 24 (60.0) | 0.297 |
Absent | 0 (0.0) | 12 (30.0) | |